Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 7

Results For "USA"

901 News Found

Biotium unveils ViaPlex 2-Color Cell Barcoding Kit to supercharge flow cytometry
News | March 20, 2026

Biotium unveils ViaPlex 2-Color Cell Barcoding Kit to supercharge flow cytometry

The kit features ViaPlex 405 Barcoding Dye for the 405 nm laser/Pacific Blue filter and ViaPlex 488 Barcoding Dye for the 488 nm laser/FITC filter


Zydus and Torrent Pharma to co-market Semaglutide injection in India
News | March 19, 2026

Zydus and Torrent Pharma to co-market Semaglutide injection in India

Zydus has developed an innovative formulation of Semaglutide Injection in a prefilled cartridge administered using a reusable patient-friendly pen device


Zydus, Lupin join forces to expand access to semaglutide in India
News | March 18, 2026

Zydus, Lupin join forces to expand access to semaglutide in India

The deal also includes upfront licensing fees and milestone-based payments from Lupin to Zydus


Aptar Pharma teams up with COVIRIX Medical to explore next-generation antiviral inhaler
R&D | March 16, 2026

Aptar Pharma teams up with COVIRIX Medical to explore next-generation antiviral inhaler

COVIRIX Medical says its broad-spectrum antiviral portfolio has already shown positive virology results against key pandemic threats


Single-use gloves misused across India, raising health risks
Healthcare | March 14, 2026

Single-use gloves misused across India, raising health risks

One task, one interaction, one pair, experts advocate


BPL Medical Tech acquires South Korea’s Yozma BMtech
News | March 12, 2026

BPL Medical Tech acquires South Korea’s Yozma BMtech

Launches advanced bone density systems in India & Dubai


FDA grants priority review to Enhertu for high-risk HER2-positive breast cancer
News | March 10, 2026

FDA grants priority review to Enhertu for high-risk HER2-positive breast cancer

Enhertu recently received Breakthrough Therapy Designation, accelerating development and review for this critical patient population


argenx reports breakthrough Phase 3 results for VYVGART in ocular myasthenia gravis
Clinical Trials | March 06, 2026

argenx reports breakthrough Phase 3 results for VYVGART in ocular myasthenia gravis

The trial met its primary endpoint, showing statistically significant improvements in Myasthenia Impairment Index (MGII) Patient-Reported Outcome (PRO) ocular scores at Week 4